Company Encyclopedia
View More
name
Chugai Pharmaceutical
CHGCY.US
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd.
4.582 T
CHGCY.USMarket value -Rank by Market Cap -/-

Financial Score

18/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking7/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE21.52%A
    • Profit Margin32.72%A
    • Gross Margin69.91%A
  • Growth ScoreC
    • Revenue YoY5.05%C
    • Net Profit YoY1.48%C
    • Total Assets YoY0.93%C
    • Net Assets YoY0.38%C
  • Cash ScoreC
    • Cash Flow Margin305.60%C
    • OCF YoY5.05%C
  • Operating ScoreB
    • Turnover0.57B
  • Debt ScoreA
    • Gearing Ratio13.44%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Chugai Announces Positive Phase 3 Results for Oral GLP-1 Orforglipron in Weight Maintenance Trial

    Chugai Pharmaceutical Co., Ltd. announced positive Phase 3 results for orforglipron, an oral GLP-1 receptor agonist, in the ATTAIN-MAINTAIN trial. The trial showed successful weight maintenance at 52 weeks compared to placebo after initial weight loss with injectable GLP-1 therapies. Eli Lilly has submitted orforglipron to the FDA for obesity treatment.

    Reuters·
    US
    CHGCY
    +1.11%
    Reuters·
    US
    CHGCY
    +1.11%

    Chugai Pharmaceutical Receives CDP A-Ratings for Climate Change and Water Security

    Chugai Pharmaceutical Co. Ltd. has been awarded A-ratings by CDP for Climate Change and Water Security, marking four consecutive years for Climate Change and three for Water Security. The company aims to achieve its 2030 environmental goals, collaborating with Roche and external partners. This news brief was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    CHGCY
    +1.11%
    Reuters·
    US
    CHGCY
    +1.11%

    Chugai Announces Roche Data Showing Giredestrant Cuts Breast Cancer Recurrence Risk by 30%

    Chugai Pharmaceutical announced that Roche's new clinical data shows giredestrant reduces the risk of invasive disease recurrence or death by 30% in estrogen receptor-positive early-stage breast cancer patients. The data was presented at the San Antonio Breast Cancer Symposium 2025. Further details are available in the Roche press release.

    Reuters·
    US
    CHGCY
    +1.11%
    Reuters·
    US
    CHGCY
    +1.11%

    Chugai Pharmaceutical Opens U.S. Partnering Office in South San Francisco

    Chugai Pharmaceutical Co. Ltd. will open a new partnering office in South San Francisco in January 2026. This office, part of Chugai Pharma USA, Inc., aims to enhance global brand recognition and foster innovation through collaborations with U.S. academia, venture capitalists, and start-ups. The expansion strengthens Chugai's global partnering framework and investment activities in the U.S.

    Reuters·
    US
    CHGCY
    +1.11%
    Reuters·
    US
    CHGCY
    +1.11%

    Chugai Reports Vabysmo Sustains Vision Gains at 48 Weeks in Angioid Streaks Trial

    Chugai Pharmaceutical Co. Ltd. announced positive 48-week results from the Phase III NIHONBASHI trial of Vabysmo® in Japanese patients with angioid streaks. The trial showed sustained vision gains and reduced retinal edema, with Vabysmo being well tolerated. Vabysmo is the first approved drug in Japan for choroidal neovascularization associated with angioid streaks. The results were presented at the Japanese Retina and Vitreous Society's 64th Annual Meeting.

    Reuters·
    US
    CHGCY
    +1.11%
    Reuters·
    US
    CHGCY
    +1.11%
    © 2025 Longbridge｜Disclaimer